Welcome to our dedicated page for Lumos Pharma news (Ticker: LUMO), a resource for investors and traders seeking the latest updates and insights on Lumos Pharma stock.
Lumos Pharma Inc (NASDAQ: LUMO) is a clinical-stage biotechnology company pioneering therapies for rare endocrine disorders, with a focus on pediatric growth hormone deficiencies. This page aggregates official press releases, clinical trial updates, and strategic developments directly from the company and verified sources.
Investors and stakeholders will find timely updates on LUMO’s pipeline progress, including its lead oral growth hormone secretagogue LUM-201, regulatory milestones, and collaborative research initiatives. The curated content spans clinical data disclosures, partnership announcements, and scientific presentations relevant to rare disease therapeutics.
Key categories include Phase 2 trial results, FDA communications, intellectual property updates, and research collaborations. All materials are sourced to ensure compliance with financial reporting standards and medical accuracy.
Bookmark this page for streamlined access to Lumos Pharma’s latest advancements in transforming treatment paradigms for underserved patient populations. Regularly updated to reflect the company’s evolving role in rare disease innovation.
Lumos Pharma (NASDAQ: LUMO) is holding a Virtual KOL Event today, April 27, 2021, at 10:30 AM ET, featuring new data on its lead asset, LUM-201, for pediatric growth hormone deficiency (PGHD).
KOLs will present findings from the Merck 020 study, highlighting LUM-201's efficacy in increasing pulsatile growth hormone release. Data demonstrates that PEM-positive subjects experienced significant height velocity increases, while one PEM-negative subject showed no benefits.
The event will include corporate updates and a Q&A session.
Lumos Pharma announces key executive changes as of April 20, 2021, marking a year since its merger. Carl Langren, CFO since November 2018, will retire on July 4, 2021, transitioning to a consulting role. Lori Lawley, with over 14 years of experience, will succeed him. Additionally, Eddie L. Varnado joins as Vice President of Finance and Corporate Controller, bringing 15 years of expertise in the biomedical sector. The leadership changes aim to strengthen Lumos' financial strategy as it advances clinical programs for its lead candidate, LUM-201, targeting pediatric growth hormone deficiency.
Lumos Pharma (NASDAQ: LUMO) is set to host a key opinion leader webinar on LUM-201 for treating pediatric growth hormone deficiency on April 27, 2021, at 10:30 AM ET. The event will feature presentations from renowned experts Dr. Bradley S. Miller and Dr. Fernando Cassorla, discussing available treatments and unmet needs in PGHD. LUM-201 is a promising oral therapy aiming to increase GH secretion while reducing the need for injections. A corporate update will also be presented, showcasing its clinical program.
Lumos Pharma (NASDAQ: LUMO) announced enhanced results for LUM-201 in treating pediatric growth hormone deficiency (PGHD) at the ENDO 2021 conference.
The data revealed that LUM-201 elicited a significant peak growth hormone (GH) response of 15.0 ng/mL in children, outperforming standard GH secretagogues, which achieved 5.4 ng/mL. Notably, this study involved 68 prepubertal children, indicating LUM-201's therapeutic potential for about 60% of the PGHD population. LUM-201's promising results support its continued development as an alternative to daily injections.
AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO) announces participation in several virtual investor conferences in March 2021. Highlights include:
- H.C. Wainwright Global Life Sciences Conference on March 10, 2021 with a pre-recorded presentation.
- Oppenheimer 31st Annual Healthcare Conference on March 17, 2021 with a live presentation and one-on-one meetings.
- 33rd Annual Roth Conference on March 15-17, 2021 featuring presentations and meetings.
Lumos Pharma focuses on developing therapeutics for rare diseases and is evaluating LUM-201 for Pediatric Growth Hormone Deficiency.
Lumos Pharma, Inc. (NASDAQ:LUMO) reported financial results for 2020, highlighting significant achievements including the completion of a merger and the receipt of $26 million from a PRV sale.
They initiated the Phase 2b OraGrowtH210 Trial for LUM-201 targeting pediatric growth hormone deficiency (PGHD). Key insights from studies published in the Journal of Endocrine Society show predictive enrichment markers for patient enrollment in clinical trials. The company anticipates a net loss of $5.7 million for 2020, a decrease from $9.7 million in 2019, with ongoing plans for research and development.
Lumos Pharma has announced the publication of analyses supporting the use of Predictive Enrichment Markers (PEMs) in its ongoing Phase 2b OraGrowtH210 Trial for treating Pediatric Growth Hormone Deficiency (PGHD). Data from previous studies identified two PEMs: a baseline IGF-1 level > 30 ng/ml and peak GH level ≥ 5 ng/mL. The findings indicate that about 60% of diagnosed children with GHD meet PEM criteria, suggesting a targeted patient population for LUM-201 treatment. The company aims to establish an oral alternative to current injection therapies.
Lumos Pharma (NASDAQ:LUMO) will present poster 7102 at the virtual Endocrine Society 2021 Annual Meeting from March 20-23, 2021. The presentation titled LUM-201 Elicits Greater GH Response than Standard GH Secretagogues in Pediatric Growth Hormone Deficiency will be held on March 20, 2021, at 11:00AM ET. LUM-201 is a promising oral therapy for Pediatric Growth Hormone Deficiency, currently undergoing a Phase 2b clinical trial.
Lumos Pharma (NASDAQ:LUMO) will report its full year 2020 financial results on March 9, 2021, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results and provide updates on clinical and corporate activities. Investors can access the live audio via a provided link or by phone. Lumos Pharma focuses on therapeutics for rare diseases, with its lead candidate LUM-201 under evaluation for Pediatric Growth Hormone Deficiency in a Phase 2b trial. The company has received Orphan Drug Designation for LUM-201 in both the US and EU.
Lumos Pharma has appointed An van Es-Johansson, M.D., to its Board of Directors, effective immediately. With over 30 years of experience in rare diseases and clinical development, she will bring valuable expertise as Lumos focuses on its Phase 2b trial for the treatment of pediatric growth hormone deficiency. Dr. van Es-Johansson succeeds Emmett Cunningham, who is resigning to concentrate on his role at Blackstone Life Sciences. The leadership change is expected to enhance Lumos Pharma’s strategic direction and clinical programs.
FAQ
What is the current stock price of Lumos Pharma (LUMO)?
What is the market cap of Lumos Pharma (LUMO)?
